Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Exclusion criteria

• ✕. patients with uncontrolled diabetes mellitus or a fasting plasma glucose \> 250mg/dl (14 mMol/L)
• ✕. patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia including a corrected QT (QTc) interval longer than 450 msec, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment
• ✕. patients with liver disease such as severe hepatic impairment (Child Pugh C), chronic active hepatitis or chronic persistent hepatitis with abnormal coagulation (INR\>1.5).
• ✕. patients with the presence of active or suspected acute or chronic uncontrolled infection
• ✕. hypersensitivity to somatostatin analogues or any component of pasireotide formulations
• ✕. patients with uncontrolled hypothyroidism